Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Dicer-substrate siRNA inhibits tumor necrosis factor alpha secretion in Kupffer cells in vitro: in vivo targeting of Kupffer cells by siRNA-liposomes.
Pharmacological research·2011
Same author
Inhibition of tumor necrosis factor alpha secretion in rat Kupffer cells by siRNA: in vivo efficacy of siRNA-liposomes.
Biochimica et biophysica acta·2007
Related Experiment Video
Updated: Jun 23, 2026
08:40
Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
siRNA for inflammatory diseases.
1Thomas Jefferson University, Department of Pathology, Anatomy and Cell Biology, 264 Jefferson Alumni Hall, 1020 Locust Street, Philadelphia, PA 19107, USA. Biddanda.Ponnappa@jefferson.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|May 12, 2009
Summary
Small interfering RNAs (siRNAs) show promise for treating inflammatory diseases. Challenges in delivery and off-target effects remain, but localized treatments are advancing therapeutic applications.
Area of Science:
- Biotechnology
- Molecular Biology
- Immunology
Background:
- Inflammation is a common response to infection, but uncontrolled inflammation can lead to severe conditions like organ failure and cancer.
- Small interfering RNAs (siRNAs) offer a potential therapeutic avenue for managing inflammatory diseases.
Purpose of the Study:
- This review summarizes recent advancements in using siRNAs for treating inflammatory conditions in the liver, lungs, joints, and colon.
- It highlights the progress and challenges in developing siRNA-based therapies for inflammatory diseases.
Main Methods:
- The review synthesizes findings from in vitro cell culture studies and preclinical/clinical investigations.
- It focuses on target identification, efficacy, and delivery system development for siRNAs.
Main Results:
- In vitro studies demonstrate high efficacy and successful target identification for siRNAs.
- Preclinical and clinical studies show promise for siRNA therapy in joint, lung, and colon inflammation, particularly with non-systemic delivery methods.
Conclusions:
- While in vitro results are encouraging, significant challenges persist, including effective in vivo delivery systems, off-target effects, and interferon responses.
- Localized siRNA delivery strategies show potential for treating specific inflammatory diseases, paving the way for future therapeutic development.